- enrolling by invitationNA
Real-time Acoustic Biofeedback for Enhancing Fixation Stability: A Proof-of-concept Study to Improve Ophthalmic Imaging Diagnostic Quality
This study looks at a new device that uses sound to help people with vision loss focus their eyes better. It aims to improve how well eye scans work for conditions like retinal dystrophies and geographic atrophy. We're also checking how easy it is for people to use.
Germany - active not recruitingPHASE3
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
This study is looking into a new treatment called vonaprument for an eye condition called geographic atrophy (GA), which is a severe form of dry age-related macular degeneration (AMD). Researchers want to see if regular injections of vonaprument into the eye can help slow down or prevent vision loss.
United States · Australia · Austria - authorisedHuman Pharmacology (Phase I)- First administration to humans
Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
This early-stage study is looking at a new medicine called Pozelimab for an eye condition called Geographic Atrophy. It's the first time this medicine is being given to people, to understand if it's safe and how it works in the body.
Romania - active not recruitingNA
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD
This study is testing a new bionic vision system called PRIMA for people with a severe eye condition called geographic atrophy, a type of age-related macular degeneration (AMD). It aims to see if PRIMA can help people regain some central vision and if it's safe to use.
France · Germany · Italy - ongoing, recruitingTherapeutic confirmatory (Phase III)
AN OPEN-LABEL EXTENSION (OLE) PHASE 3 TRIAL TO ASSESS THE SAFETY OF INTRAVITREAL ADMINISTRATION OF AVACINCAPTAD PEGOL (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY WHO PREVIOUSLY COMPLETED PHASE 3 STUDY ISEE2008 (GATHER2)
This study is looking at the long-term safety of a medicine called Avacincaptad pegol for people with a serious eye condition called geographic atrophy. It's for those who have already been in a previous study using this medicine.
Hungary · Belgium · France - recruiting
Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression
This study looks at how a specific type of age-related macular degeneration (AMD) progresses. It uses AI and eye scans to understand changes over two years, aiming to personalize future monitoring for people with this AMD.
Austria · France · Slovenia - not yet recruitingPHASE2
A Study in Adults With Geographic Atrophy
This study is testing a new medicine, STL303, for Geographic Atrophy (GA), an eye condition that can cause blurry central vision. We want to see if it's safe and effective in slowing down this vision loss for people aged 60 and over.
United States · Argentina · Australia - active not recruitingPHASE3
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy
This study is testing a new medicine, tinlarebant, for a serious eye condition called Geographic Atrophy (GA). Researchers want to see if it's safe and helps improve or slow down GA. It's a key step in finding new treatments.
United States · Australia · China - active not recruiting
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
This study looks at how a serious eye condition called Geographic Atrophy (GA) develops over time. GA is a type of 'dry' Age-related Macular Degeneration (AMD). Researchers are checking for 'biomarkers' in blood and how they relate to changes in the eye.
United States · United Kingdom - recruitingPHASE2
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study looks at the long-term safety of a new eye treatment, JNJ-81201887, for geographic atrophy, a type of macular degeneration. It checks how people who received this treatment in earlier studies are doing over time.
United States · Australia · Belgium - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
This study is testing a new eye treatment called JNJ-81201887 for a condition called Geographic Atrophy (GA). GA is a serious eye problem linked to ageing that can cause blurry vision. Researchers want to see if this new treatment can slow down the worsening of GA.
Netherlands · Belgium · Germany